Viewing nowLyrica Capsule 75 mg (Pregabalin)
Pregabalin 75mg
Hard capsule · Prescription medication
Baskan Bio Pharmaceutical Co., Ltd.

MFDS item code 201702149 · Approved 2017.04.27 · Insurance code 656204750
Treatment of neuropathic pain; adjunctive treatment of partial-onset seizures; treatment of fibromyalgia
This medicine is used to relieve peripheral and central neuropathic pain in adults. Additionally, it serves as an adjunctive treatment for partial seizures in epilepsy patients, whether or not accompanied by secondary generalized symptoms. It is also effective for pain relief caused by fibromyalgia. In other words, it is used for neuropathic pain, adjunctive treatment of partial seizures in epilepsy, and treatment of fibromyalgia.
The total daily dose of this medicine, as pregabalin, is administered orally in 2 divided doses, with or without food. Since this medicine is primarily excreted by the kidneys, the dose should be adjusted in patients with impaired renal function. (See section ‘5. Patients with renal impairment’.) 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: This medicine may be given at an initial dose of 150 mg daily. Based on the individual patient’s response and tolerability, the dose may be increased to 300 mg daily after 3 to 7 days. If needed, it may subsequently be increased at 7-day intervals up to a maximum of 600 mg daily. 2) Central neuropathic pain Adults: This medicine may be given at an initial dose of 150 mg daily. Based on the individual patient’s response and tolerability, the dose may be increased to 300 mg daily after 1 week. After an additional week, it may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered. (See section ‘4. Discontinuation’.) 2. Epilepsy Adults: This medicine may be given at an initial dose of 150 mg daily. Based on the individual patient’s response and tolerability, the dose may be increased to 300 mg daily after 1 week. If needed, it may subsequently be increased at 7-day intervals up to a maximum of 600 mg daily. 3. Fibromyalgia The recommended dose of this medicine for fibromyalgia is 300 mg to 450 mg daily. The initial dose is 75 mg twice daily (150 mg daily), and based on efficacy and tolerability, it may be increased within 1 week to 150 mg twice daily (300 mg daily). For patients who do not experience sufficient benefit at a dose of 300 mg daily, the dose may be increased within 1 week to 225 mg twice daily (450 mg daily). Clinical studies have also been conducted at a dose of 600 mg daily, but there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450 mg daily are not recommended. 4. Discontinuation Based on current clinical experience, if treatment with this medicine is discontinued, it should be withdrawn gradually over at least 1 week. 5. Patients with renal impairment This medicine is primarily excreted by the kidneys as unchanged drug after entering the systemic circulation. Since the clearance of this medicine is directly affected by creatinine clearance, dose reduction in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined using the formula below. *: For women, multiply the result obtained from the above calculation by 0.85. This medicine is effectively removed from plasma by hemodialysis (approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, a supplemental dose should be administered promptly after each 4-hour hemodialysis session. [Table 1]. Pregabalin dosage based on renal function Creatinine clearance (CLcr), (mL/min) Total daily dose of pregabalin a Administration schedule Initial dose (mg/day) Maximum dose (mg/day) ≥60 150 600 BID or TID ≥30 -<60 75 300 BID or TID ≥15 -<30 25-50 150 QD or BID <15 25 75 QD Supplemental dose after hemodialysis 25 100 Single dose b TID = Total daily dose divided into 3 doses BID = Total daily dose divided into 2 doses QD = Once daily a: The total daily dose (mg/day) should be divided as specified in the administration schedule. b: A supplemental dose is an additional dose administered once. 6. Patients with hepatic impairment No dosage adjustment is necessary in patients with hepatic impairment. 8. Older adults (65 years of age or older) Dose reduction may be necessary in older adults with impaired renal function.
7. Pediatric and adolescent patients Administration is not recommended for children under 12 years of age or adolescent patients aged 12 to 17 years because there are insufficient data on safety and efficacy.
This medication may increase the risk of suicidal thoughts or behavior, so patients should inform their doctor or caregiver immediately if they experience symptoms of depression, mood changes, or unusual behavior during treatment. This medication should not be taken by individuals with hypersensitivity to the drug or genetic issues such as lactose intolerance. Patients with diabetes may find it difficult to control blood sugar due to weight gain; therefore, adjustments to diabetes medication dosage may be necessary. If symptoms of angioedema develop, the medication should be stopped immediately, and elderly patients should be cautious as they are at a higher risk of falling due to dizziness or drowsiness. This medication may cause blurred vision or changes in vision, so patients should consult with their doctor if symptoms occur. Discontinuing the medication abruptly can lead to withdrawal symptoms such as insomnia, headaches, and anxiety, so the dosage should be gradually reduced according to the doctor's instructions. Patients with a history of substance abuse may have a higher risk of dependence on this medication, so special caution is necessary while taking it. Patients with decreased kidney function may need dosage adjustments. Patients with heart diseases should be careful while taking this medication, as concurrent use with opioid analgesics may increase the risk of central nervous system depression. Patients with respiratory or neurological diseases, as well as the elderly, face a risk of severe respiratory depression, so dosage adjustments should be made according to a doctor's instructions. In early pregnancy, the risk of fetal malformation exists, so pregnant women should avoid taking this medication, and women of childbearing potential should use effective contraception. Lactating women should consult with their doctor regarding whether to discontinue breastfeeding or the medication due to the drug potentially being transmitted through breast milk. This medication may cause dizziness and drowsiness; thus, caution is required when driving or operating hazardous machinery. If severe skin rashes or allergic symptoms occur, discontinue use and visit a medical institution immediately. In case of overdose, symptoms such as confusion, drowsiness, and depression may appear, and emergency treatment such as hemodialysis may be required. This medication should be stored out of the reach of children and should not be transferred to another container.
suicidal impulses, suicidal behaviors, depression, abnormal changes in mood and behavior, angioedema, facial swelling, perioral edema, upper airway edema, dizziness, drowsiness, loss of consciousness, confusion, mental disorders, blurred vision, changes in vision, insomnia, headaches, nausea, anxiety, diarrhea, influenza-like syndrome, restlessness, suicidal thoughts, pain, seizures, hyperhidrosis, misuse, abuse, dependence, hypoglycemia, increased appetite, anorexia, confusion, disorientation, irritability, euphoria, decreased libido, depersonalization, hyperesthesia, restlessness, anxiety, mood swings, emotional lability, emotional elevation, hallucinations, abnormal dreams, increased libido, panic attacks, loss of impulse control, apathy, ataxia, motor coordination abnormalities, balance disorders, memory loss, attention deficit, memory impairment, tremors, dysphonia, sensory disturbances, sensory loss, sedation, drowsiness, cognitive impairment, nystagmus, speech disorders, myoclonus, diminished reflexes, movement abnormalities, psychomotor agitation, position-related dizziness, perceptual hypersensitivity, burning sensation, tremors during activity, syncope, confusion, hypokinesia, olfactory disturbances, loss of taste, writing difficulties, double vision, vertigo, auditory hypersensitivity, first-degree AV block, tachycardia, bradycardia, polymorphic ventricular tachycardia, hypotension, hypertension, flushing, facial flushing, peripheral coldness, respiratory distress, epistaxis, cough, nasal congestion, rhinitis, snoring, pharyngeal tension, nasal dryness, respiratory depression, vomiting, abdominal distension, constipation, dry mouth, bloating, excessive salivation, gastroesophageal reflux disease, oral sensory loss, ascites, dysphagia, pancreatitis, sweating, papulovesicular rash, urticaria, cold sweat, muscle cramps, arthralgia, back pain, limb pain, cervical spasms, joint swelling, myalgia, muscle spasms, neck pain, muscle stiffness, rhabdomyolysis, urination disorders, urinary incontinence, decreased urination, renal failure, erectile dysfunction, delayed ejaculation, sexual dysfunction, dysmenorrhea, amenorrhea, mastalgia, breast discharge, gynecomastia, peripheral edema, edema, gait disturbances, falls, sensation of intoxication, altered sensation, fatigue, tightness in the chest, generalized edema, pain, fever, chills, weakness, thirst, weight gain, increased alanine aminotransferase, increased creatine phosphokinase in blood, increased aspartate aminotransferase, increased blood sugar, decreased platelet count, decreased potassium levels in blood, weight loss, increased creatinine in blood, decreased white blood cell count, hypersensitivity, allergic reactions, headaches, keratitis, congestive heart failure, pulmonary edema, nausea, diarrhea, tongue swelling, itching, Stevens-Johnson syndrome, toxic epidermal necrolysis, urinary retention, gynecomastia, lethargy, delirium, paralysis (facial paralysis), affective disorder, drowsiness, state of confusion, agitation, restlessness, worsening of seizures, gastrointestinal disturbances, tinnitus, sleep disorders, skin diseases, increased BUN, blood in stools, shock, anaphylaxis-like symptoms, mucocutaneous syndrome, erythema multiforme
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly closed container to protect it from air and moisture. The recommended storage temperature is between 15 to 30 degrees Celsius.
Hard capsule with a reddish-brown top and white bottom containing white powder that is white or light yellow.
30 capsules/bottle, 60 capsules/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowPregabalin 75mg
Hard capsule · Prescription medication
Baskan Bio Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 300mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Samjin Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Samjin Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Hanmi Pharm. Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Hanmi Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.